Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of atopic dermatitis (AD) in canines and felines. In a second aspect, the MSCs or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used as an immunomodulating agent during the acute and/or the chronic phase of the AD inflammatory reaction in canines and felines diagnosed with or suffering from atopic dermatitis. In a last aspect, a pharmaceutical composition comprises peripheral blood-derived MSCs.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of chronic gingivostomatitis (CGS) in subjects, preferably in felines and canines. In a second aspect, MSCs or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used as an immunomodulating agent during the acute and/or the chronic phase of the CGS inflammatory reaction in subjects, preferably in felines and canines diagnosed with or suffering from chronic gingivostomatitis. In a last aspect, a pharmaceutical composition can comprise peripheral blood-derived MSCs.

Mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising a therapeutically effective amount of MSCs can be used in the treatment of chronic kidney disease in felines and canines. Creatinine levels in felines and canines diagnosed with or suffering from chronic kidney disease can be reduced compared to a feline or canine which has not been treated with said MSCs or composition. A pharmaceutical composition comprises MSCs derived from peripheral blood.

The embodiments of the present disclosure provide a manufacturing method of mitochondria-rich plasma. The mitochondria-rich plasma can increase the cell viability of damaged cells, decrease the cellular senescence level, repair the oxidative damage of cells, and relieve the inflammation of hair follicles so as to achieve the purpose of promoting hair regrowth.

Among the various aspects of the present disclosure is the provision of methods and compositions for upregulating MHC class II in cancer cells (e.g., a hematological cancer cell). Also provided are methods of treatment for subjects suffering from hematological cancers, comprising administration of interferon-γ (IFN-γ). The methods of treatment provided herein may be particularly suitable for subjects who have received an allogenic transplant or have suffered a relapse.

Among the various aspects of the present disclosure is the provision of methods and compositions for upregulating MHC class II in cancer cells (e.g., a hematological cancer cell). Also provided are methods of treatment for subjects suffering from hematological cancers, comprising administration of interferon-γ (IFN-γ). The methods of treatment provided herein may be particularly suitable for subjects who have received an allogenic transplant or have suffered a relapse.

The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

Wound dressing assembly including (i) blood-clotting mold device having an enclosure defined between walls of a main body and a removable closure over an opening and configured for introduction of blood thereinto, and (ii) coagulation initiator in amount sufficient to coagulate blood introduced into the enclosure to form a blood clot. The formed blood clot is transferable onto a wound. Method for preparing a wound dressing by introducing a volume of blood into the enclosure of the blood-clotting mold device, maintaining the blood within the enclosure for time sufficient to permit clotting of the blood to obtain a blood clot; removing the closure to open the enclosure; and extracting the blood clot from the enclosure. The formed blood clot may be used in a method for dressing a wound by fixation of the clot onto the wound.

Wound dressing assembly including (i) blood-clotting mold device having an enclosure defined between walls of a main body and a removable closure over an opening and configured for introduction of blood thereinto, and (ii) coagulation initiator in amount sufficient to coagulate blood introduced into the enclosure to form a blood clot. The formed blood clot is transferable onto a wound. Method for preparing a wound dressing by introducing a volume of blood into the enclosure of the blood-clotting mold device, maintaining the blood within the enclosure for time sufficient to permit clotting of the blood to obtain a blood clot; removing the closure to open the enclosure; and extracting the blood clot from the enclosure. The formed blood clot may be used in a method for dressing a wound by fixation of the clot onto the wound.